1-3 of 3
Samuel Y. Ng
Close
Sort by
Journal Articles

Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL

Clinical Trials & Observations
Inhye E. Ahn, Danielle M. Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Heather A. Walker, Robert Black, Josie Montegaard, Alvaro Alencar, Leyla Shune, Mohammad Omaira, Caron A. Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer Crombie, David C. Fisher, Ann S. LaCasce, Jon Arnason, Ephraim P. Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (4): 832–841.
https://doi.org/10.1182/bloodadvances.2023011574
Published: 2024
Includes: Supplemental data
Journal Articles

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

Reid W. Merryman, Robert A. Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M. McHugh, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Eric Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O. Odejide, Erin M. Parry, Heather Jacene, Hyesun Park, Parastoo B. Dahi, Yago Nieto, Robin M. Joyce, Yi-Bin Chen, Margaret A. Shipp, Alex F. Herrera, Philippe Armand
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4748–4759.
https://doi.org/10.1182/bloodadvances.2022007706
Published: 2023
Includes: Supplemental data
Journal Articles

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation

Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jennifer L. Crombie, Caron A. Jacobson, Eric D. Jacobsen, Jeffrey L. Wong, Jad Bsat, Sanjay S. Patel, Jerome Ritz, Scott J. Rodig, Margaret A. Shipp, Yi-Bin Chen, Robin M. Joyce
Journal: Blood Advances
Blood Adv (2020) 4 (1): 122–126.
https://doi.org/10.1182/bloodadvances.2019000784
Published: 2020
Includes: Supplemental data